Nama's AI scorecard currently rates Aurinia Pharmaceuticals Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AUPH's P/E ratio?

Aurinia Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.2.

When does AUPH report earnings?

Aurinia Pharmaceuticals's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.21.

What is the AUPH price target?

The median analyst price target from 7 analysts is $18.00, with a range of $16.00 – $21.00.

Is AUPH Shariah compliant?

Nama's AAOIFI-style screen reads Aurinia Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Aurinia Pharmaceuticals (AUPH)

Healthcare · Biotechnology · NASDAQ

Aurinia Pharmaceuticals (AUPH) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.21B, a trailing price-to-earnings ratio of 7.2 and a free-cash-flow yield of 6.0%. Over the most recent reported fiscal year, revenue grew 20.4% and free cash flow per share grew 223.6%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 8.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +14.8% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-49.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.21B
Trailing P/E	7.2
Price / book	3.6
Price / sales	6.9
FCF yield	6.0%
Dividend yield	—
Gross margin	90.4%
Operating margin	48.4%
Net margin	100.8%
Revenue growth (YoY)	+20.4%
Revenue growth (3-yr annual)	+28.3%
EPS growth (YoY)	+4060.0%
FCF/share growth (YoY)	+223.6%
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

AUPH earnings

Next report: Mar 1, 2027 (Q4 2026, EPS estimate $0.21). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 30, 2026	$0.23	$0.22	+4.5%	$83.70M
Q2 2026	Aug 6, 2026	$0.28	$0.24	+16.7%	$83.22M
Q1 2026	May 7, 2026	$0.25	$0.20	+25.0%	$77.70M
Q4 2025	Feb 26, 2026	$1.53	$0.22	+595.5%	$77.11M

AUPH analyst price target

Median target $18.00 from 7 analysts, ranging $16.00 – $21.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live AUPH data on Nama Insights →

AUPH FAQ

Is AUPH a buy?: Nama's AI scorecard currently rates Aurinia Pharmaceuticals Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AUPH's P/E ratio?: Aurinia Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.2.
When does AUPH report earnings?: Aurinia Pharmaceuticals's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.21.
What is the AUPH price target?: The median analyst price target from 7 analysts is $18.00, with a range of $16.00 – $21.00.
Is AUPH Shariah compliant?: Nama's AAOIFI-style screen reads Aurinia Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.